Hepatitis B vs Hepatitis C: Key Differences in Symptoms, Treatment, and Monitoring

Hepatitis B and hepatitis C are both viral infections that attack the liver — but that's where most of the similarities end. They're caused by different viruses, spread in different ways, have very different treatment options, and require different monitoring strategies. Understanding these differences is critical whether you've been diagnosed with one (or both), or you're a caregiver seeking clarity.

This guide breaks down everything you need to know about hepatitis B and hepatitis C in patient-friendly language: how each virus works, how they're transmitted, what symptoms to watch for, the landmark differences in treatment (including the fact that hepatitis C is now curable), and why tracking your liver health is essential regardless of which virus you have.

⚡ Check Your Liver Health Now

Whether you have hepatitis B, C, or both — your liver enzymes and function tests tell you how your liver is doing. Use our free Liver Enzyme Checker to understand your ALT, AST, and other values, or take the Liver Health Quiz for a quick risk assessment.

What Are Hepatitis B and Hepatitis C?

Both hepatitis B and hepatitis C are viral infections that cause inflammation of the liver. "Hepatitis" literally means "liver inflammation." While there are five main types of viral hepatitis (A through E), B and C are the two most likely to become chronic (long-lasting) and cause serious liver damage over time.

Hepatitis B (HBV)

Hepatitis B is caused by the hepatitis B virus (HBV), a DNA virus. It is one of the most common infectious diseases in the world, affecting over 250 million people with chronic infection globally, causing nearly 900,000 deaths annually from cirrhosis and liver cancer. HBV is vaccine-preventable — a highly effective vaccine has been available since the 1980s.

Hepatitis C (HCV)

Hepatitis C is caused by the hepatitis C virus (HCV), an RNA virus. An estimated 58 million people worldwide have chronic HCV infection, with approximately 2.4–4 million in the United States alone. Unlike hepatitis B, there is no vaccine for hepatitis C. However, the game-changing development is that hepatitis C is now curable in over 95% of cases with modern antiviral medications.

How Are They Transmitted? Key Differences

One of the most important differences between HBV and HCV is how they spread:

A key distinction: hepatitis B is much more easily transmitted sexually than hepatitis C. HBV is 50–100 times more infectious than HIV. Hepatitis C, on the other hand, spreads primarily through direct blood-to-blood contact, with shared needles being the most common route in developed countries.

Acute vs. Chronic: What Happens After Infection

After the virus enters your body, the first 6 months are called the acute phase. What happens next depends on which virus you have and your age at infection:

Hepatitis B: Acute to Chronic

• Adults: Approximately 90–95% of healthy adults who get hepatitis B will clear the virus on their own within 6 months and develop lifelong immunity. Only 5–10% develop chronic infection.

• Children: The younger you are at infection, the higher the risk of chronicity. Infants infected at birth have a 90% chance of developing chronic HBV. Children infected between ages 1–5 have a 25–50% chance.

• This is why perinatal transmission (mother to child) is such a critical issue globally — and why newborn vaccination is so important.

Hepatitis C: Acute to Chronic

• Hepatitis C behaves very differently — approximately 55–85% of people who get HCV will develop chronic infection, regardless of age.

• Only 15–45% clear the virus spontaneously during the acute phase.

• This high chronicity rate is why hepatitis C became such a massive public health problem — most people who catch it keep it.

Symptoms: The Silent Infections

Both hepatitis B and C are often called "silent" infections because many people have no symptoms at all — sometimes for decades — while the virus quietly damages their liver. This is one of the most dangerous aspects of both diseases.

When symptoms do appear, they can include fatigue and low energy, nausea and loss of appetite, abdominal pain (especially upper right side), dark urine and pale or clay-colored stools, joint pain, jaundice (yellowing of skin and eyes), and general malaise.

The symptoms of hepatitis B and C are virtually identical — you cannot tell which virus you have based on symptoms alone. Only blood tests can distinguish them. This is why universal screening is so important, and why monitoring your liver function tests regularly matters even if you feel perfectly fine.

Long-Term Consequences: What Both Viruses Can Do to Your Liver

If left untreated, both chronic hepatitis B and C can lead to the same serious complications over years to decades:

• Liver fibrosis: Progressive scarring of liver tissue. Detectable early with a FibroScan — use our FibroScan Interpreter to understand your results.

• Cirrhosis: Advanced scarring that disrupts liver function. Approximately 15–25% of people with chronic hepatitis B or C develop cirrhosis. Read more in our cirrhosis stages guide.

• Liver cancer (HCC): Both viruses significantly increase the risk of hepatocellular carcinoma. HBV is unique in that it can cause liver cancer even without cirrhosis (because the virus integrates into the host DNA).

• Liver failure: End-stage liver disease requiring transplant.

• Decompensation complications: Ascites, variceal bleeding, and hepatic encephalopathy.

The timeline differs: hepatitis B can cause liver damage over 20–30 years of chronic infection. Hepatitis C typically takes 20–30 years to progress to cirrhosis as well, but the rate can be accelerated by alcohol use, co-infection with HIV or HBV, obesity, or male sex.

Treatment: The Biggest Difference Between HBV and HCV

This is where hepatitis B and C diverge most dramatically:

Hepatitis C: Curable

The development of direct-acting antivirals (DAAs) has been one of the greatest breakthroughs in modern medicine. These oral medications target the hepatitis C virus directly and can cure HCV in over 95% of patients in just 8–12 weeks of treatment with minimal side effects.

Key DAA medications include sofosbuvir/velpatasvir (Epclusa), glecaprevir/pibrentasvir (Mavyret), and sofosbuvir/ledipasvir (Harvoni). In 2025, the FDA expanded glecaprevir/pibrentasvir's label to include treatment of acute HCV — achieving a 96% cure rate in just 8 weeks.

A patient is considered cured (called "sustained virologic response" or SVR) when no HCV RNA is detectable in their blood 12 weeks after completing treatment. Cure eliminates the risk of further liver damage from HCV, halts fibrosis progression, and in many cases leads to fibrosis regression. Even patients with decompensated cirrhosis can achieve recompensation after HCV cure — a recent study showed 67.6% of decompensated patients achieved recompensation within 12 months of SVR.

Important: Even after cure, patients with advanced fibrosis or cirrhosis still need ongoing monitoring for liver cancer (HCC screening every 6 months) because the cancer risk persists even after the virus is eliminated.

Hepatitis B: Treatable But Not Yet Curable

Unlike hepatitis C, there is currently no cure for chronic hepatitis B. The virus persists in the liver cell nucleus as covalently closed circular DNA (cccDNA) — a stable reservoir that current medications cannot eliminate. However, effective long-term treatment exists:

Nucleos(t)ide Analogues (NAs) — the mainstay of treatment:

• Tenofovir (TDF or TAF) and entecavir — first-line medications that suppress HBV replication to undetectable levels in most patients

• These drugs do NOT cure the infection but they prevent liver damage from progressing, reduce the risk of cirrhosis and liver cancer, and can be taken safely for years or even decades

• Some patients may need to take NAs for life, particularly those with cirrhosis

Pegylated Interferon-alpha (PEG-IFN): An immune-modulating injection given for a finite course (usually 48 weeks). It works by boosting the immune system's ability to fight HBV. Response rates are lower than NAs, but some patients achieve "functional cure" (loss of HBsAg).

The 2025 EASL guidelines introduced a significant shift: for selected non-cirrhotic patients with sustained viral suppression and very low HBsAg levels, carefully supervised treatment discontinuation may be attempted — with 20–30% achieving sustained off-treatment control and a smaller proportion achieving functional cure (HBsAg loss).

Prevention: Vaccine and Beyond

The hepatitis B vaccine is one of the most effective vaccines ever developed — it provides over 95% protection and is part of routine childhood vaccination schedules worldwide. If you haven't been vaccinated, talk to your doctor about getting the vaccine.

For hepatitis C, since no vaccine exists, prevention relies on avoiding exposure — primarily through harm reduction programs, safe injection practices, and screening. The CDC recommends that all adults aged 18 and older get tested for HCV at least once in their lifetime.

Can You Have Both Hepatitis B and C?

Yes — co-infection with both HBV and HCV is possible and occurs in approximately 2–10% of HBV-positive patients (higher in certain populations like people who inject drugs). Co-infection is associated with more severe liver disease, faster progression to cirrhosis, and a higher risk of liver cancer.

An important clinical concern: when treating hepatitis C in a patient who also has hepatitis B, curing HCV can sometimes trigger HBV reactivation — a dangerous flare of the hepatitis B virus. The 2025 AGA guidelines specifically address this risk and recommend HBV testing before starting HCV treatment and antiviral prophylaxis or close monitoring for patients with HBV co-infection.

If you have both viruses, it's essential that your hepatologist coordinates your treatment carefully. Track both your HBV and HCV labs using LiverTracker's report tracker — our AI extracts all relevant values and helps you monitor both conditions simultaneously.

Monitoring Your Liver: Why It Matters for Both

Regardless of whether you have hepatitis B, hepatitis C, or have been cured of HCV, ongoing liver monitoring is essential. Here's why and what to track:

For Chronic Hepatitis B

• HBV DNA (viral load): Shows whether the virus is actively replicating — the key measure of treatment effectiveness

• HBsAg (quantitative): Recommended every 1–2 years to monitor treatment response and assess proximity to functional cure

• Liver function tests (ALT, AST): Elevated ALT signals active liver inflammation. Use the Liver Enzyme Checker to understand your values.

• FibroScan: To assess and monitor fibrosis. Track with the FibroScan Tracker.

• HCC surveillance: Ultrasound + AFP every 6 months for patients with cirrhosis or at high risk. Log imaging with imaging tracking.

• MELD score and Child-Pugh class: Essential if cirrhosis develops. Calculated automatically when you upload labs to LiverTracker.

For Chronic Hepatitis C (Before and After Cure)

• Before treatment: HCV RNA (viral load), genotype, liver function tests, FibroScan, and possibly liver biopsy to assess fibrosis stage and guide treatment decisions

• During treatment: HCV RNA at specified intervals to confirm the virus is declining

• 12 weeks after treatment (SVR check): HCV RNA — if undetectable, you are cured

• After cure: If you had advanced fibrosis (F3) or cirrhosis (F4), you still need ongoing HCC surveillance (ultrasound + AFP every 6 months) because the cancer risk persists even after the virus is eliminated

• After cure, ongoing lab monitoring: Track your liver function tests to confirm sustained improvement. Use trend tracking to see how your values improve post-cure

📊 Track Everything in One Place

LiverTracker's report tracker lets you upload every lab report — our AI extracts ALT, AST, bilirubin, albumin, INR, creatinine, sodium, platelets, and more. Your MELD, Child-Pugh, and clinical scores are calculated automatically. The FibroScan Tracker and imaging tracker capture your FibroScan results and ultrasound reports. And the AI health chat can answer questions like "Is my liver improving after treatment?"

The Complete Side-by-Side Comparison

Frequently Asked Questions

Which is worse — hepatitis B or hepatitis C?

Neither is inherently "worse" — both can cause serious liver damage including cirrhosis and liver cancer if untreated. However, hepatitis C is now curable in over 95% of cases, while hepatitis B requires long-term management. From a treatment standpoint, a hepatitis C diagnosis in 2026 has a much more straightforward path to resolution. Hepatitis B, while not curable, can be effectively managed for decades with antivirals.

Can you have both at the same time?

Yes — co-infection is possible and requires coordinated management. Treating HCV in co-infected patients carries a risk of HBV reactivation. Your hepatologist should test for both viruses and manage them simultaneously.

If hepatitis C is cured, do I still need to monitor my liver?

If you had advanced fibrosis (F3) or cirrhosis (F4) before cure — yes, absolutely. The risk of liver cancer remains elevated even after the virus is eliminated. You should continue HCC screening (ultrasound + AFP every 6 months) and regular liver function monitoring. Upload your labs to LiverTracker to track your post-cure improvements.

Should I get tested for hepatitis B and C?

Yes. The CDC recommends universal hepatitis B and C screening for all adults. Many people are infected without knowing it because the viruses can be silent for decades. A simple blood test can detect both. Early detection leads to better outcomes.

Can I prevent hepatitis B if I've been exposed?

If you've been exposed to HBV and haven't been vaccinated, post-exposure prophylaxis (hepatitis B immune globulin + vaccine) can prevent infection if given within 24 hours of exposure. The hepatitis B vaccine series can also be started immediately. For hepatitis C, there is no post-exposure prophylaxis — but early testing and treatment can cure the infection before liver damage occurs.

How do I know if my hepatitis treatment is working?

For hepatitis B: undetectable HBV DNA on treatment, normal or improving ALT levels, stable or improving FibroScan results. For hepatitis C: declining HCV RNA during treatment, undetectable HCV RNA 12 weeks after treatment (SVR = cure). Track all of these with LiverTracker's report tracker and trend tracking.

Medical References & Sources

1. PMC. Chronic hepatitis B in 2025: diagnosis, treatment and future directions. 2025 EASL Guidelines Review. PMC Full Text

2. Mayo Clinic. Hepatitis B and Hepatitis C: What's the difference? December 2025. Mayo Clinic

3. CDC. Clinical Overview of Viral Hepatitis. August 2025. CDC

4. WHO. Consolidated guidance on hepatitis B and C prevention, testing, treatment, service delivery and monitoring. 2025. WHO Publication

5. HCPLive. Hepatitis in 2025: Year in Review. December 2025. HCPLive

6. Frontiers in Medicine. Editorial: Chronic hepatitis B management: current status and future directions. 2025. Frontiers Full Text

Related Articles & Tools on LiverTracker

• Hepatitis C Condition Guide

• Complete Guide to Liver Function Tests

• What Is a FibroScan? How Non-Invasive Liver Testing Works

• Cirrhosis Stages Explained: From Compensated to Decompensated

• Portal Hypertension and Varices: What Every Liver Patient Should Know

• Living with Ascites: Causes, Symptoms, and How to Track Fluid Retention

• What Is MELD Score? A Patient-Friendly Guide

• Understanding the Liver Transplant Waiting List

• NAFLD vs NASH: What's the Difference?

• Liver Enzyme Checker Tool

• FibroScan Interpreter Tool

• MELD Score Calculator

• Liver Health Quiz

• Browse All Articles

🎯 Take Control of Your Liver Health Today

Whether you're living with hepatitis B, cured of hepatitis C, or monitoring your liver health for any reason — LiverTracker has you covered. Upload lab reports, track FibroScan results, monitor all your trends, log imaging results, get AI-powered health answers, and share everything with your doctor.

→ Check Your Liver Enzymes Free

→ Create Your Free Account

→ Download the iOS App

Medical Disclaimer: This article is for informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your hepatologist, gastroenterologist, or infectious disease specialist for guidance specific to your condition. LiverTracker does not provide medical advice. For our complete disclaimer, visit livertracker.com/medical-disclaimer.